The borderline significant interaction of canagliflozin treatment and stroke prevention with baseline use of an antithrombotic is likely to reflect a chance finding consequent upon the many comparisons made rather than a real effect.
2
—
—
The sentences
The rate of ischemic stroke was also lower among those treated with canagliflozin compared with placebo (n=253; HR, 0.95; 95% CI, 0.74–1.22), but this did not reach statistical significance.